Health insurers will shell out $743 million in rebates to consumers under an Affordable Care Act (ACA) rule; the human papilloma virus (HPV) vaccine offers benefits to men who are not vaccinated; Apple is launching 3 studies to assess the Apple Watch’s ability to monitor health and medical conditions.
Under an Affordable Care Act rule requiring health insurers to provide consumers rebates if they don’t spend a large enough share of premium dollars on healthcare, 2.7 consumers are expected to get a record $743 million this month, according to an analysis from the Kaiser Family Foundation. The figure is 4 times the amount paid out last year, reported The Wall Street Journal, and consumers who get this year’s rebates are expected to get an average of $270. Insurers will also pay employers $534 million this year under the same rule.Men who have not been vaccinated against human papilloma virus (HPV) may still reap some benefits from the vaccine, according to a new study published in JAMA. The study found that rates of oral cancer—related HPV strains in unvaccinated men dropped from 2.7% in 2009-2010 to 1.6% in 2015-2016, likely reflecting a herd immunity effect from the vaccine. While the findings are not a surprise, they do come as a relief, as HPV-associated head and neck cancers are rapidly increasing among young men, reported NBC News.Apple has announced that it will partner with the National Institutes of Health and the American Heart Association, as well as academic medical centers, to launch 3 studies that will determine if the Apple Watch can effectively monitor women’s medical conditions, hearing health, and mobility signals, such as heart rate. According to STAT News, the observational studies are projected to start enrolling participants later this year and will initially be conducted entirely virtually.
Eculizumab Biosimilar ABP 959 Demonstrates Similarity to Reference in Patients With PNH
December 6th 2023ABP 959, an eculizumab biosimilar in development, has demonstrated similar efficacy and pharmacokinetics to the reference product for patients with paroxysmal nocturnal hemoglobinuria (PNH), according to research at the 2023 American Society of Hematology Annual Meeting.
Read More
Humana Report Shows Benefits of Value-Based Care for Patients, Physicians
December 6th 2023Patients seen at value-based care clinics received more preventive screenings and had lower risks of hospitalization and emergency room visits, according to Humana’s 10th annual value-based care report.
Read More
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More